Literature DB >> 12711614

Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?

C Robin Hiley1, William R Ford.   

Abstract

Endocannabinoid production by platelets and macrophages is increased in circulatory shock. This may be protective of the cardiovascular system as blockade of CB(1) cannabinoid receptors exacerbates endothelial dysfunction in haemorrhagic and endotoxin shock and reduces survival. Now evidence suggests that blockade of CB(1) receptors starting 24 h after myocardial infarction in rats has a deleterious effect on cardiac performance, while use of a nonselective cannabinoid receptor agonist prevents hypotension and reduces endothelial dysfunction, although left ventricular end diastolic pressure is elevated. Cannabinoids and endocannabinoid systems may therefore present useful targets for therapy following myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711614      PMCID: PMC1573769          DOI: 10.1038/sj.bjp.0705155

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

Review 1.  Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators.

Authors:  V Di Marzo
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

2.  The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery.

Authors:  R White; C R Hiley
Journal:  Br J Pharmacol       Date:  1998-10       Impact factor: 8.739

3.  Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.

Authors:  M A Pfeffer; S C Greaves; J M Arnold; R J Glynn; F S LaMotte; R T Lee; F J Menapace; E Rapaport; P M Ridker; J L Rouleau; S D Solomon; C H Hennekens
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

4.  Endogenous cannabinoids mediate hypotension after experimental myocardial infarction.

Authors:  J A Wagner; K Hu; J Bauersachs; J Karcher; M Wiesler; S K Goparaju; G Kunos; G Ertl
Journal:  J Am Coll Cardiol       Date:  2001-12       Impact factor: 24.094

5.  Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide.

Authors:  C Lagneux; D Lamontagne
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

6.  CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.

Authors:  Jens A Wagner; Kai Hu; Jan Karcher; Johann Bauersachs; Andreas Schäfer; Martin Laser; Hong Han; Georg Ertl
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

7.  Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.

Authors:  William R Ford; Stuart A Honan; Richard White; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 8.  Cardiovascular actions of cannabinoids and their generation during shock.

Authors:  J A Wagner; K Varga; G Kunos
Journal:  J Mol Med (Berl)       Date:  1998 Nov-Dec       Impact factor: 4.599

Review 9.  Prevention of ventricular remodelling post myocardial infarction: timing and duration of therapy.

Authors:  B I Jugdutt
Journal:  Can J Cardiol       Date:  1993 Jan-Feb       Impact factor: 5.223

Review 10.  Cardiovascular effects of cannabinoids.

Authors:  Michael D Randall; David Harris; David A Kendall; Vera Ralevic
Journal:  Pharmacol Ther       Date:  2002-08       Impact factor: 12.310

  10 in total
  7 in total

Review 1.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 3.  Cardiovascular pharmacology of cannabinoids.

Authors:  P Pacher; S Bátkai; G Kunos
Journal:  Handb Exp Pharmacol       Date:  2005

Review 4.  Blood pressure regulation by endocannabinoids and their receptors.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Neuropharmacology       Date:  2005-02-19       Impact factor: 5.250

Review 5.  Exploration of Multiverse Activities of Endocannabinoids in Biological Systems.

Authors:  Tapan Behl; Rashita Makkar; Aayush Sehgal; Sukhbir Singh; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Abdulkarim M Meraya; Simona Bungau
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

Review 6.  Endocannabinoids and the heart.

Authors:  C Robin Hiley
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

7.  Harm reduction--the cannabis paradox.

Authors:  Robert Melamede
Journal:  Harm Reduct J       Date:  2005-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.